These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29219670)

  • 1. Expanding the use of abiraterone in prostate cancer: Is earlier always better?
    Schmidt KT; Madan RA; Figg WD
    Cancer Biol Ther; 2018 Feb; 19(2):97-100. PubMed ID: 29219670
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    Taneja SS
    J Urol; 2018 Jan; 199(1):26-28. PubMed ID: 29310181
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
    Struss WJ; Black PC
    Urology; 2017 Nov; 109():1-2. PubMed ID: 28797683
    [No Abstract]   [Full Text] [Related]  

  • 4. Abiraterone and its place in the treatment of metastatic CRPC.
    Sartor O; Pal SK
    Nat Rev Clin Oncol; 2013 Jan; 10(1):6-8. PubMed ID: 23149889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
    Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
    Karakurt Eryılmaz M; Karaağaç M
    J Oncol Pharm Pract; 2019 Dec; 25(8):2031-2034. PubMed ID: 31694496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
    Sorensen S; Ellis L; Wu Y; Hutchins V; Linnehan JE; Senbetta M
    J Manag Care Pharm; 2013; 19(9):799-808. PubMed ID: 24156649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
    Khalaf DJ; Sunderland K; Eigl BJ; Kollmannsberger CK; Ivanov N; Finch DL; Oja C; Vergidis J; Zulfiqar M; Gleave ME; Chi KN
    Eur Urol; 2019 Jun; 75(6):940-947. PubMed ID: 30591354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.
    Lin GW; Li GX; Dai B; Ye DW; Kong YY; Wang Y; Shen YJ
    Asian J Androl; 2019; 21(2):131-136. PubMed ID: 30560837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer.
    Parikh M; Liu C; Wu CY; Evans CP; Dall'Era M; Robles D; Lara PN; Agarwal N; Gao AC; Pan CX
    Sci Rep; 2021 Mar; 11(1):6377. PubMed ID: 33737681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
    Tagawa ST; Beltran H
    Asian J Androl; 2011 Nov; 13(6):785-6. PubMed ID: 21857690
    [No Abstract]   [Full Text] [Related]  

  • 16. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
    Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Auchus RJ; Yu MK; Nguyen S; Mundle SD
    Oncologist; 2014 Dec; 19(12):1231-40. PubMed ID: 25361624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone and increased survival in metastatic prostate cancer.
    de Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Fléchon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Kheoh T; Haqq CM; Scher HI;
    N Engl J Med; 2011 May; 364(21):1995-2005. PubMed ID: 21612468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Abiraterone in castration resistant prostate cancer.].
    Juárez Soto A; Caballero Cobos R; Campanario Pérez R; Saiz Marenco R; Herrera Torres M; Gamaza Martínez R; Amores Bermúdez J
    Arch Esp Urol; 2018 Sep; 71(8):651-663. PubMed ID: 30319125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.